Clinical trials: Borderline Resectable Pancreatic Carcinoma
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.
CTCs, Pancreatic Cancer
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning…
- Conditions
- CTCs, Pancreatic Cancer, Liver Metastases, Relapse
- Trial name
- NCT07448376
- Testing
- CTC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Pancreatic Adenocarcinoma, Pancreatic Cancer
Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma
Pancreatic cancer represents the 11th most commonly diagnosed cancer in men and 9th in women, being the third leading cause of cancer-related death in the Western countries.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreas Neoplasm
- Trial name
- NCT03649035
- Testing
- HTP treatment
- Where
- Italy
- Sponsor
- Istituto Clinico Humanitas
Borderline Resectable Pancreatic Cancer
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
The aim of this study is to evaluate the safety and efficacy of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
- Trial name
- NCT04855331
- Testing
- Laparoscopic pancreatoduodenectomy, Open pancreatoduodenectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Pancreatic Cancer
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen.
- Trial name
- NCT03983057
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Zhejiang University
Pancreatic Cancer
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
This trial is a prospective, single-arm, single-center Phase II clinical study aimed at evaluating the efficacy and safety of Ivonescimab combined with the gemcitabine and nab-paclitaxel (AG) regimen as neoadjuvant therapy for…
- Trial name
- NCT06944106
- Testing
- AK112
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy.
- Trial name
- LAPTOP (NCT04247165)
- Testing
- Gemcitabine, Nab-paclitaxel, Nivolumab
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Herlev Hospital
Resectable Pancreatic Cancer
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients.
- Trial name
- NCT03392571
- Testing
- NGC-Triple regimen
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial…
- Trial name
- NCT06141031
- Testing
- TTI-101, Stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Pancreatic Neoplasms
SBRT Pre-operatively for Pancreatic Cancer
In this study the investigators are testing if the addition of Stereotactic Body Radiation therapy (SBRT) prior to surgery improves surgical outcome in patients with borderline resectable or resectable pancreatic cancer (BRPC).
- Trial name
- SPARC (NCT02308722)
- Testing
- 5-fraction stereotactic body radiation therapy
- Where
- 5 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Pancreas Cancer, Adenocarcinoma
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
Despite important therapeutic advances, pancreatic adenocarcinoma remains one of the cancers with a high mortality rate (4th leading cause of cancer death in the US in 2021), poor prognosis (5-year overall survival rate of 10%)…
- Trial name
- ReMeTTI (NCT05511116)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Pancreatic Neoplasms, Pancreatic Cancer
Project Survival-Prospective Biomarker Discovery
This sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma
- Trial name
- NCT02781012
- Where
- 6 sites in United States
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreas Cancer
Surgical Results of Resection of Locally Advanced Pancreatic Cancer
The aim is to compare the surgical outcomes between upfront surgery and surgery after neoadjuvant chemotherapy in terms of morbidity and mortality
- Trial name
- NCT06206382
- Testing
- Whipple operation
- Volunteers
- 80 people
- Sponsor
- Assiut University
Pancreatic Cancer, Adult
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
- Trial name
- NCT07436741
- Testing
- surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital